BR112013018516A2 - constructo de ácido nucléico para expressão de alfa-galactosidade em plantas e células de plantas - Google Patents
constructo de ácido nucléico para expressão de alfa-galactosidade em plantas e células de plantasInfo
- Publication number
- BR112013018516A2 BR112013018516A2 BR112013018516-3A BR112013018516A BR112013018516A2 BR 112013018516 A2 BR112013018516 A2 BR 112013018516A2 BR 112013018516 A BR112013018516 A BR 112013018516A BR 112013018516 A2 BR112013018516 A2 BR 112013018516A2
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- expression
- alpha
- plant cells
- plants
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title abstract 5
- 102000039446 nucleic acids Human genes 0.000 title abstract 5
- 108020004707 nucleic acids Proteins 0.000 title abstract 5
- 102000005840 alpha-Galactosidase Human genes 0.000 abstract 3
- 108010030291 alpha-Galactosidase Proteins 0.000 abstract 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
Abstract
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161434499P | 2011-01-20 | 2011-01-20 | |
US201161434503P | 2011-01-20 | 2011-01-20 | |
US61/434,503 | 2011-01-20 | ||
US61/434,499 | 2011-01-20 | ||
ILPCT/IL2011/000209 | 2011-03-02 | ||
PCT/IL2011/000209 WO2011107990A1 (en) | 2010-03-02 | 2011-03-02 | Stabilized alpha-galactosidase and uses thereof |
PCT/IL2011/000719 WO2012098537A1 (en) | 2011-01-20 | 2011-09-07 | Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013018516A2 true BR112013018516A2 (pt) | 2019-05-21 |
BR112013018516B1 BR112013018516B1 (pt) | 2023-11-07 |
Family
ID=44786043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013018516-3A BR112013018516B1 (pt) | 2011-01-20 | 2011-09-07 | Construto de expressão de ácido nucleico, método de produção de uma proteína alfa-galactosidase humana recombinante, proteína alfagalactosidase humana, composição farmacêutica, e, uso de uma proteína alfagalactosidase humana ou de uma composição |
Country Status (18)
Country | Link |
---|---|
US (1) | US9732333B2 (pt) |
EP (2) | EP2665814B1 (pt) |
JP (1) | JP5913372B2 (pt) |
KR (1) | KR101883803B1 (pt) |
CN (1) | CN103443270B (pt) |
AU (1) | AU2011356137A1 (pt) |
BR (1) | BR112013018516B1 (pt) |
CA (1) | CA2824791A1 (pt) |
CY (1) | CY1122794T1 (pt) |
DK (2) | DK3272861T3 (pt) |
ES (1) | ES2774190T3 (pt) |
IL (1) | IL227552B (pt) |
LT (1) | LT3272861T (pt) |
PL (1) | PL3272861T3 (pt) |
PT (1) | PT3272861T (pt) |
RS (1) | RS60129B1 (pt) |
SI (1) | SI3272861T1 (pt) |
WO (1) | WO2012098537A1 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009024977A2 (en) | 2007-08-20 | 2009-02-26 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
JP5913372B2 (ja) | 2011-01-20 | 2016-04-27 | プロタリクス リミテッド | 植物および植物細胞におけるα−ガラクトシダーゼの発現のための核酸発現構築物 |
BR112015021708A2 (pt) | 2013-03-06 | 2017-08-29 | Protalix Ltd | Inibidor de polipetídeo do tnfa, polinucleotídeo isolado, estrutura de expressão de ácido nucleico, célula de planta, composição farmacêutica e método de produção de um inibidor de polipeptídeo do tnfa |
BR112015021707A2 (pt) * | 2013-03-06 | 2017-12-05 | Hadasit Med Res Service | uso de células de planta que expresam um inibidor de polipeptídeo tnfalfa em terapia. |
TW202332774A (zh) * | 2013-10-23 | 2023-08-16 | 美商健臻公司 | 重組醣蛋白及其用途 |
MX2017011510A (es) | 2015-03-17 | 2018-01-11 | Greenovation Biotech Gmbh | Proteinas lisosomales glicosiladas, metodo de produccion y usos. |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
CA3048151A1 (en) * | 2017-01-05 | 2018-07-12 | Protalix Ltd. | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase |
IL257269A (en) * | 2018-01-31 | 2018-04-09 | Olender Tsviya | Signaling is directed to the endoplasmic reticulum |
KR102209198B1 (ko) * | 2019-04-02 | 2021-02-02 | 주식회사 바이오앱 | 식물에서의 발현이 최적화된 재조합 이리신 유전자 및 이를 이용한 재조합 이리신 단백질의 생산 방법 |
KR102213745B1 (ko) | 2019-04-16 | 2021-02-09 | 주식회사 바이오앱 | 돼지 유행성 설사병 바이러스 백신 조성물 및 이의 제조 방법 |
WO2020256372A1 (ko) | 2019-06-17 | 2020-12-24 | 주식회사 바이오앱 | 아프리카 돼지열병의 진단을 위한 항원 생산용 재조합 벡터 및 이의 용도 |
WO2023027402A1 (ko) | 2021-08-27 | 2023-03-02 | 주식회사 바이오앱 | 아프리카 돼지열병 바이러스 유래 항원 단백질을 포함하는 아프리카 돼지열병의 예방용 백신 |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
CA1192510A (en) | 1981-05-27 | 1985-08-27 | Lawrence E. Pelcher | Rna plant virus vector or portion thereof, a method of construction thereof, and a method of producing a gene derived product therefrom |
JPS6054684A (ja) | 1983-09-05 | 1985-03-29 | Teijin Ltd | 新規dνa及びハイブリツドdνa |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
CA1288073C (en) | 1985-03-07 | 1991-08-27 | Paul G. Ahlquist | Rna transformation vector |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
GB8608850D0 (en) | 1986-04-11 | 1986-05-14 | Diatech Ltd | Packaging system |
JPS6314693A (ja) | 1986-07-04 | 1988-01-21 | Sumitomo Chem Co Ltd | 植物ウイルスrnaベクタ− |
ES2060646T3 (es) | 1987-02-09 | 1994-12-01 | Lubrizol Genetics Inc | Virus rna hibrido. |
US6846968B1 (en) * | 1988-02-26 | 2005-01-25 | Large Scale Biology Corporation | Production of lysosomal enzymes in plants by transient expression |
US5316931A (en) | 1988-02-26 | 1994-05-31 | Biosource Genetics Corp. | Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes |
US5693507A (en) | 1988-09-26 | 1997-12-02 | Auburn University | Genetic engineering of plant chloroplasts |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5936035A (en) | 1988-11-21 | 1999-08-10 | Cohesion Technologies, Inc. | Biocompatible adhesive compositions |
US5614587A (en) | 1988-11-21 | 1997-03-25 | Collagen Corporation | Collagen-based bioadhesive compositions |
US5179023A (en) | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
US5302523A (en) | 1989-06-21 | 1994-04-12 | Zeneca Limited | Transformation of plant cells |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
DE4009630C2 (de) | 1990-03-26 | 1995-09-28 | Reinhard Prof Dr Dr Brossmer | CMP-aktivierte fluoreszierende Sialinsäuren sowie Verfahren zu ihrer Herstellung |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
UA48104C2 (uk) | 1991-10-04 | 2002-08-15 | Новартіс Аг | Фрагмент днк, який містить послідовність,що кодує інсектицидний протеїн, оптимізовану для кукурудзи,фрагмент днк, який забезпечує направлену бажану для серцевини стебла експресію зв'язаного з нею структурного гена в рослині, фрагмент днк, який забезпечує специфічну для пилку експресію зв`язаного з нею структурного гена в рослині, рекомбінантна молекула днк, спосіб одержання оптимізованої для кукурудзи кодуючої послідовності інсектицидного протеїну, спосіб захисту рослин кукурудзи щонайменше від однієї комахи-шкідника |
WO1993018148A2 (en) | 1992-03-12 | 1993-09-16 | Wisnieski Bernadine J | Tumor necrosis factor with modified channel activity |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
JPH08506247A (ja) | 1993-07-09 | 1996-07-09 | アムジェン ボールダー インコーポレイテッド | 組換えctla4ポリペプチドおよびその製造方法 |
US6329191B1 (en) | 1993-08-30 | 2001-12-11 | Hawaii Biotechnology Group, Inc. | DNA encoding recombinant coffee bean alpha-galactosidase |
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US5994086A (en) | 1994-03-30 | 1999-11-30 | North Shore University Hospital | Method for assessing infertility by binding of mannose to sperm cells |
JPH10513057A (ja) | 1995-01-30 | 1998-12-15 | ニューヨーク・ブラッド・センター・インコーポレイテッド | 組換えα−ガラクトシダーゼ酵素 |
EP0865499B1 (en) | 1995-09-14 | 2009-03-18 | Virginia Tech Intellectual Properties, Inc. | Production of lysosomal enzymes in plant-based expression systems |
US6309646B1 (en) | 1996-05-09 | 2001-10-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates |
US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
IL119310A (en) | 1996-09-26 | 1999-07-14 | Metabogal Ltd | Cell/tissue culturing device and method |
IL155588A0 (en) | 2003-04-27 | 2003-11-23 | Metabogal Ltd | Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby |
US20050032211A1 (en) | 1996-09-26 | 2005-02-10 | Metabogal Ltd. | Cell/tissue culturing device, system and method |
US20010008766A1 (en) | 1998-03-17 | 2001-07-19 | Sylvia Daunert | Quantitative binding assays using green fluorescent protein as a label |
IL125423A (en) | 1998-07-20 | 2004-08-31 | Israel State | Alkaline alpha-galactosidase having broad substrate specificity |
AU7645700A (en) | 1999-10-07 | 2001-05-10 | Maxygen Aps | Single-chain antagonist polypeptides |
US7244823B2 (en) | 2000-03-02 | 2007-07-17 | Xencor | TNF-alpha variants proteins for the treatment of TNF-alpha related disorders |
US7687461B2 (en) | 2000-03-02 | 2010-03-30 | Xencor, Inc. | Treatment of TNF-α related disorders with TNF-α variant proteins |
US20070172449A1 (en) | 2000-03-02 | 2007-07-26 | Xencor, Inc. | TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS |
US7001994B2 (en) | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
BR0116803A (pt) | 2001-01-18 | 2004-02-17 | Merck Patent Gmbh | Proteìnas de fusão bifuncionais com atividade de glicocerebrosidase |
MEP38608A (en) | 2001-10-22 | 2011-02-10 | Merck Serono Sa | Gonadotrophins for folliculogenesis |
WO2003042244A2 (en) | 2001-11-16 | 2003-05-22 | Pharmexa A/S | Immunogenic mimetics of multimer proteins with promiscuous t cell epitope inserts |
ES2367257T3 (es) | 2002-04-25 | 2011-10-31 | Shire Human Genetic Therapies, Inc. | Tratamiento de deficit de alfa-galactosidasa a. |
CA2427190A1 (en) * | 2002-04-30 | 2003-10-30 | Alberta Research Council Inc. | Production of recombinant epidermal growth factor in plants |
DE60330779D1 (de) | 2002-05-15 | 2010-02-11 | Agricultural Res Org | Für alkalische a-galactosidasen codierende polynukleotidsequenzen und verfahren zur verwendung davon |
US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
US7855063B2 (en) | 2003-04-16 | 2010-12-21 | Yeda Research And Development Co. Ltd. | Partially deglycosylated glucocerebrosidase polypeptide and crystals thereof |
US7951557B2 (en) * | 2003-04-27 | 2011-05-31 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
GB2402677A (en) | 2003-05-06 | 2004-12-15 | Sirus Pharmaceuticals Ltd | Biodegradable polymer |
WO2004111198A2 (en) | 2003-06-12 | 2004-12-23 | Genzyme Corporation | Modified human acid sphingomyelinase having increased activity, and methods for making the same |
JP2005043317A (ja) | 2003-07-25 | 2005-02-17 | Olympus Corp | 糖鎖と生体分子との反応を検出する方法 |
US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
WO2005046722A2 (en) | 2003-11-05 | 2005-05-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer |
WO2005056760A2 (en) | 2003-12-03 | 2005-06-23 | Neose Technologies, Inc. | Glycopegylated follicle stimulating hormone |
WO2005077093A2 (en) | 2004-02-06 | 2005-08-25 | Biomarin Pharmaceutical Inc. | Manufacture of highly phosphorylated lysosomal enzymes and uses thereof |
WO2006093524A2 (en) | 2004-07-16 | 2006-09-08 | The General Hospital Corporation | Antigen-carbohydrate conjugates |
JP5137814B2 (ja) | 2005-04-06 | 2013-02-06 | ジェンザイム・コーポレーション | 治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート |
US20110070201A1 (en) | 2005-07-18 | 2011-03-24 | Protalix Ltd. | Mucosal or enteral administration of biologically active macromolecules |
KR20070065157A (ko) | 2005-12-19 | 2007-06-22 | 이수근 | 고객맞춤형 투자자산 관리기능을 갖는 인터넷뱅킹 시스템및 방법 |
EP2630972B1 (en) | 2006-07-25 | 2017-08-30 | Lipoxen Technologies Limited | N-terminal polysialylation |
WO2008075957A1 (en) | 2006-12-21 | 2008-06-26 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Treatment of fabry disease |
CN101631794B (zh) | 2007-01-18 | 2013-01-02 | 建新公司 | 包含氨基氧基基团的寡糖及其轭合物 |
EP1955712A1 (en) | 2007-02-09 | 2008-08-13 | Scil proteins GmbH | Multimeric conjugate |
EP2150608B1 (en) | 2007-05-07 | 2017-11-29 | Protalix Ltd. | Large scale disposable bioreactor |
EP2164863A4 (en) | 2007-06-15 | 2010-07-28 | Univ Arkansas | METHOD FOR THE ADMINISTRATION OF MOLECULES IN CELLS USING A RICIN SUB-UNIT AND RELATED COMPOSITIONS THEREOF |
WO2009024977A2 (en) | 2007-08-20 | 2009-02-26 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
EP2339951A1 (en) | 2008-07-10 | 2011-07-06 | Given Imaging Ltd. | Device, method and kit for in vivo detection of a biomarker |
WO2011061736A1 (en) | 2009-11-17 | 2011-05-26 | Protalix Ltd. | Alkaline alpha galactosidase for the treatment of fabry disease |
US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
NZ623294A (en) * | 2010-03-02 | 2015-10-30 | Protalix Ltd | Stabilized alpha-galactosidase and uses thereof |
WO2011107991A1 (en) | 2010-03-02 | 2011-09-09 | Protalix Ltd. | Glucocerebrosidase multimers and uses thereof |
JP5913372B2 (ja) | 2011-01-20 | 2016-04-27 | プロタリクス リミテッド | 植物および植物細胞におけるα−ガラクトシダーゼの発現のための核酸発現構築物 |
-
2011
- 2011-09-07 JP JP2013549932A patent/JP5913372B2/ja active Active
- 2011-09-07 US US13/980,910 patent/US9732333B2/en active Active
- 2011-09-07 PL PL17164713T patent/PL3272861T3/pl unknown
- 2011-09-07 EP EP11767776.5A patent/EP2665814B1/en active Active
- 2011-09-07 WO PCT/IL2011/000719 patent/WO2012098537A1/en active Application Filing
- 2011-09-07 PT PT171647134T patent/PT3272861T/pt unknown
- 2011-09-07 RS RS20200291A patent/RS60129B1/sr unknown
- 2011-09-07 ES ES17164713T patent/ES2774190T3/es active Active
- 2011-09-07 EP EP17164713.4A patent/EP3272861B1/en active Active
- 2011-09-07 DK DK17164713.4T patent/DK3272861T3/da active
- 2011-09-07 CN CN201180069560.7A patent/CN103443270B/zh active Active
- 2011-09-07 KR KR1020137021693A patent/KR101883803B1/ko active IP Right Grant
- 2011-09-07 AU AU2011356137A patent/AU2011356137A1/en not_active Abandoned
- 2011-09-07 BR BR112013018516-3A patent/BR112013018516B1/pt active IP Right Grant
- 2011-09-07 SI SI201131858T patent/SI3272861T1/sl unknown
- 2011-09-07 DK DK11767776.5T patent/DK2665814T3/en active
- 2011-09-07 LT LTEP17164713.4T patent/LT3272861T/lt unknown
- 2011-09-07 CA CA2824791A patent/CA2824791A1/en not_active Abandoned
-
2013
- 2013-07-18 IL IL227552A patent/IL227552B/en active IP Right Grant
-
2020
- 2020-03-06 CY CY20201100202T patent/CY1122794T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP2665814B1 (en) | 2017-05-17 |
LT3272861T (lt) | 2020-03-25 |
DK3272861T3 (da) | 2020-03-23 |
US9732333B2 (en) | 2017-08-15 |
EP3272861A1 (en) | 2018-01-24 |
CA2824791A1 (en) | 2012-07-26 |
CN103443270A (zh) | 2013-12-11 |
ES2774190T3 (es) | 2020-07-17 |
IL227552A0 (en) | 2013-09-30 |
PL3272861T3 (pl) | 2020-07-13 |
CY1122794T1 (el) | 2021-05-05 |
SI3272861T1 (sl) | 2020-06-30 |
EP3272861B1 (en) | 2019-12-18 |
KR20140015330A (ko) | 2014-02-06 |
CN103443270B (zh) | 2017-06-06 |
PT3272861T (pt) | 2020-03-26 |
BR112013018516B1 (pt) | 2023-11-07 |
WO2012098537A8 (en) | 2013-08-08 |
WO2012098537A1 (en) | 2012-07-26 |
US20130295065A1 (en) | 2013-11-07 |
AU2011356137A1 (en) | 2013-08-15 |
EP2665814A1 (en) | 2013-11-27 |
RS60129B1 (sr) | 2020-05-29 |
JP5913372B2 (ja) | 2016-04-27 |
DK2665814T3 (en) | 2017-09-11 |
KR101883803B1 (ko) | 2018-07-31 |
IL227552B (en) | 2018-05-31 |
JP2014506450A (ja) | 2014-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013018516A2 (pt) | constructo de ácido nucléico para expressão de alfa-galactosidade em plantas e células de plantas | |
IL272324B (en) | Methods, systems and preparations for cellular conversion using protein-induced in vivo cellular programming | |
CL2016001065A1 (es) | Locus genómicos óptimos de maíz para la inserción de genes exógenos y método para producir una célula vegetal transgénica. | |
CL2016001190A1 (es) | Cultivo de células de mamífero. | |
BR112015003149A2 (pt) | células natural killer e usos das mesmas. | |
BRPI1010010A2 (pt) | Derivados de primidina-4-il-propanodinitrila, método para sua fabricação bem como seu uso como herbicidas e reguladores de crescimento de planta | |
UY35351A (es) | Formulaciones acuosas estables de adalimumab | |
AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
BR112014010455A2 (pt) | Métodos para produzir um anticorpo, usos de il-e2 e/ou il-21, métodos para cultivar uma célula, usos de uma célula de mamífero e uso de sac no co- cultivo de células b | |
BR112012009921A2 (pt) | métodos para reprogramar células e usos do mesmos | |
BR112012018021A2 (pt) | antídotos anticoagulantes. | |
UY33974A (es) | Molécula de adn que codifica elementos regulatorios de plantas, célula vegetal, planta y semilla transgénicas,métodos para obtenerlas y productos | |
BR112014006292A2 (pt) | método para redução do coeficiente, método para produção de uma população de plantas, método para redução do número de plantas, construção e vetor de expressão recombinante, célula transgênica ou planta transgênica, uso de uma molécula e método para a produção de um produto agrícola | |
BR112013005855A2 (pt) | heteroarilas fundidas e seus usos | |
PT2760282T (pt) | Instalação de piscicultura, módulo, processo e utilização | |
CL2013001621A1 (es) | Molecula de acido nucleico reguladora con especificidad definida, construccion de expresion que la comprende, vector; microorganismo, celula vegetal o animal; y metodo para la produccion de dicha molecula. | |
CL2012002568A1 (es) | Metodo para mejorar los rasgos relacionados con el rendimiento en plantas en relación con las plantas control que comprende modular la expresión en una planta de un acido nucleico que codifica un polipeptido tipo cle2; constructo que codifica polipeptido cle2; uso de dicho constructo para producir planta con mayor rendimiento , en particular mayor biomasa y/o mayor rendimiento de semillas. | |
BRPI0922484A2 (pt) | Cultura de célula de planta para produção de produtos naturais com contaminação de glucosinolato reduzida | |
EP2997131A4 (en) | HUMAN PLURIPOTENTIAL STEM CELLS MADE BY SOMATIC CELL CORE TRANSFER | |
EP2831234A4 (en) | COMPOSITIONS, METHODS AND GENES OF PLANTS FOR BETTER PRODUCTION OF FERMENTABLE SUGARS FOR BIOFUELS PRODUCTION | |
CU20160153A7 (es) | Proteína antiporter de protones/azúcar tonoplastidiarias adecuadas para incrementar la concentración de sacarosa en un órgano vegetal de almacenamiento de sacarosa | |
EP2884544A4 (en) | SOLAR CELL MANUFACTURING METHOD AND SOLAR CELL PRODUCED BY THIS MANUFACTURING METHOD | |
BR112015017830A2 (pt) | processos e meios para aumentar a tolerância ao estresse e a biomassa em plantas | |
CL2014000140A1 (es) | Uso de anolito neutro para descontaminar troncos de vid; procedimiento para producir planta de vid injerto-soldada que comprende aplicar dicho anolito neutro. | |
BR112015022737A2 (pt) | construto de polinucleotídeo recombinante, célula vegetal, planta, semente, método para regular expressão |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. PAGAR RESTAURACAO. |
|
B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.6 NA RPI NO 2525 DE 28/05/2019 POR TER SIDO INDEVIDA. UMA VEZ QUE A 6A E A 7A ANUIDADE FORAM RECOLHIDAS CORRETAMENTE. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B11N | Dismissal: publication cancelled [chapter 11.14 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 11.2 NA RPI NO 2604 DE 01/12/2020 POR TER SIDO INDEVIDA. |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/09/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |